Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer.

First report for inoperable population of a phase II trial by Japan Clinical Oncology Group

(JCOG-0403)Y. Nagata*, 　 M. Hiraoka#, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura

Radiation Therapy Study Group of Japan Clinical Oncology Group*Study Coordinator, #Primary Investigator

ASTRO, Boston, Oct. 28-31, 2012.

• Stereotactic body radiation therapy (SBRT) delivers very targeted beams of radiation to a small area over a few days

• SBRT is less invasive than surgery• SBRT is considered to work against T1N0M0 lung

cancers• First report for operable population was presented in

ASTRO 2010.• This presentation is the first

report for inoperable population.

• First clinical trial to study SBRT for both inoperable & operable stage IA lung cancers

• From 2004 to 2008, 104 patients from 15 institutions with early-stage inoperable non-small cell lung cancer were studied

• Patients underwent 4 times daily radiotherapy over the course of four to eight days

• Each treatment is non-invasive and painless, much like receiving an X-ray

• Patients followed for almost three years (37 months) after treatment

• Overall survival rate for patients three years after SBRT was 60 percent

• Patients reported only mild side effects from the treatment

• Patients with inoperable early lung cancer should consider this treatment

Conv RT vs. SBRTAuthor Number Age Stage Dose (med) /

Daily dose 3-y OS 5-y OS Year

Morita 149 50-89 I 55-75 (64.7)/2Gy 34.2 22.2 1980-1989

Sibley 141 46-95 I

50-80 (64)/1.8-

3.0Gy:QD1.2-

1.6Gy:BID

39(2-y) 13 1980-1995

Krol 108 56-88 I 60-65/2.5-3Gy 31 15 1978-1992

This study 104 78 (59-

90) IA 48/12Gy 59.9* 40.8* 2004-2008

* In all eligible patients (n=100)